- Details
- Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...
|
- Details
- Ashish Kamat welcomes David D'Andrea to discuss the eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. He highlights the historical context of TURB (Transurethral Resection of Bladder Tumor) and its limited evolution over the years. The eBLOC trial, designed to compare en-bloc and conventional TURB, aimed to improve the quality of resection, crucial for accurate stag...
|
- Details
- Amanda Myers presents a comprehensive review on lymph node dissection in GU cancers as of 2023. She emphasizes its critical role in surgical urologic care for accurate staging and detecting micrometastases. The review, based on systematic research from 2014 to 2023, covers bladder, upper tract, kidney, prostate, and penile cancers. Key findings include the recommendation of standard pelvic lymph n...
|
- Details
- Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...
|
- Details
- Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...
|
- Details
- Ashish Kamat welcomes Laura Bukavina to discuss highlights from the SUO 2023 meeting, focusing on bladder cancer research. Dr. Bukavina emphasizes the BOND-003 study on cretostimogene (creto), an adenovirus targeting bladder cancer cells with defective retinoblastoma genes. Creto shows a 75.7% complete response rate, with 74.4% lasting over six months. Another key topic is the ENVISION trial, exam...
|
- Details
- Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the trial's focus on systemic therapy as an alternative to cystectomy, noting its potential for curative outcomes. The study involved patients receiving gemcitabine-cisplatin plus nivolumab, followed by clinical restaging to identify clini...
|
- Details
- Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO, show...
|
- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
- Details
- Tom Jayram hosts a panel of experts to discuss advancements in bladder cancer treatment, emphasizing personalized therapies, clinical trials, and the importance of a comprehensive approach. They highlight the role of nephron-sparing techniques and new tests in improving traditional diagnostic methods. Biographies: Tom Jayram, MD, Urology Associates P.C, Nashville, TN Daniel Saltzstein, MD, Urology...
|
